Payment overview · 2025
General Payments
$551.46
29 reported records · 15 companies
Healthcare provider profile · identity verified
Vishal Aggarwal, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · TULSA, OK · NPI 1295705663
Verified facts
What the public records show
CMS Open Payments records show Vishal Aggarwal, MD received $551.46 in general payments during 2025 across 29 reported records.
Lilly USA, LLC accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $118.15 | 21.4% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $89.37 | 16.2% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $49.37 | 8.9% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.29 | 7.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.46 | 7.3% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $33.39 | 6.0% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $31.79 | 5.8% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $24.34 | 4.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$21.99 | 4.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.16 | 3.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.23 | 3.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.04 | 3.3% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.43 | 2.8% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $14.84 | 2.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.61 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $551.46 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $89.37 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $89.37 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $73.66 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $49.37 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.49 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $44.49 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $41.29 | 2 | 2025 |
Source payment records
|
|||||
| CYGNUS DUAL Normalized: cygnus dual |
Medical Supply | Organogenesis Inc. | $33.39 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | $33.07 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $31.79 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $21.99 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 58 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
18 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
58 | 50 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 160 | 61 |
| Atorvastatin Calcium | Atorvastatin Calcium | 157 | 115 |
| Gabapentin | Gabapentin | 141 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 127 | 86 |
| Lisinopril | Lisinopril | 122 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 113 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 103 | 59 |
| Losartan Potassium | Losartan Potassium | 86 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 52 |
| Meloxicam | Meloxicam | 63 | 35 |
| Oxycodone Hcl | Oxycodone Hcl | 63 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 61 | 40 |
| Eliquis | Apixaban | 58 | 50 |
| Furosemide | Furosemide | 58 | 51 |
| Metformin Hcl | Metformin Hcl | 54 | 30 |
| Donepezil Hcl | Donepezil Hcl | 53 | 35 |
| Potassium Chloride | Potassium Chloride | 53 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 51 | 31 |
| Pregabalin | Pregabalin | 50 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 46 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 30 |
| Omeprazole | Omeprazole | 41 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | 24 |
| Carvedilol | Carvedilol | 38 | 31 |
| Trazodone Hcl | Trazodone Hcl | 38 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 33 | 26 |
| Mirtazapine | Mirtazapine | 32 | 19 |
| Sertraline Hcl | Sertraline Hcl | 32 | 19 |
| Ondansetron Odt | Ondansetron | 31 | 27 |
| Baclofen | Baclofen | 30 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 30 | 20 |
| Ozempic | Semaglutide | 30 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | 19 |
| Montelukast Sodium | Montelukast Sodium | 26 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 25 | 11 |
| Celecoxib | Celecoxib | 24 | 12 |
| Glipizide Er | Glipizide | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Methocarbamol | Methocarbamol | 22 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | 12 |
| Simvastatin | Simvastatin | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | 14 |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | 12 |
| Glipizide | Glipizide | 18 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | 12 |
| Xarelto | Rivaroxaban | 18 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 17 | 12 |
| Jardiance | Empagliflozin | 17 | suppressed |
| Prednisone | Prednisone | 17 | 14 |
| Torsemide | Torsemide | 17 | 14 |
| Atenolol | Atenolol | 16 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | 16 |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Spironolactone | Spironolactone | 15 | 12 |
| Allopurinol | Allopurinol | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 13 | 12 |
| Buspirone Hcl | Buspirone Hcl | 13 | 11 |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | 12 |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | 11 |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $551.46 · 29 records | Lilly USA, LLC | CAPLYTA, CONTRAVE, CYGNUS DUAL, Cologuard Collection Kit, ELIQUIS, INCEPTIV, JARDIANCE, KISUNLA, Leqembi, MOUNJARO, NURTEC ODT, REXULTI, SPRAVATO, VRAYLAR, XIFAXAN, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error